Roche Accelerates Development of Promising Weight-Loss Pills

Swiss pharmaceutical giant aims to challenge market leaders with new obesity treatments based on encouraging trial data.

Roche's CT-388 and CT-996 drugs are progressing to phase two trials after positive early results.
The company plans to bring its first weight-loss drug to market potentially by 2028.
Roche's pills offer an alternative to injectable treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
The global obesity drug market is projected to exceed $100 billion by 2030.
Roche's acquisition of Carmot Therapeutics has bolstered its obesity drug portfolio.